Claims

1. The use of meloxicam or a pharmacologically acceptable salt thereof for the manufacture of a medicament for the long-term treatment of musculoskeletal disorders in cats, characterised in that the treatment occurs over a long-term period of from ~~10~~ 13 to 40 months.

2. The use of meloxicam or a pharmacologically acceptable salt thereof according to claim 1, characterised in that no negative effects on renal function occur during a treatment from ~~10~~ 13 to 40 months.

3. The use of meloxicam or a pharmacologically acceptable salt thereof according to any one of claims 1 to 2, characterised in that the cats have a pre-existing renal disease.

4. The use of meloxicam or a pharmacologically acceptable salt thereof according to any one of claims 1 to 2, characterised in that the cats have no pre-existing renal disease.

5. The use of meloxicam or a pharmacologically acceptable salt thereof according to any one of claims 1 to 3, characterised in that the cats have a chronic kidney disease.

6. The use of meloxicam or a pharmacologically acceptable salt thereof according to any one of claims 1 to 5, characterised in that the daily dose is from 0.01 and 0.075 mg/kg.

7. The use of meloxicam or a pharmacologically acceptable salt thereof according to any one of claims 1 to 6, characterised in that the daily dose is from 0.02 to 0.06 mg/kg.

8. The use of meloxicam or a pharmacologically acceptable salt thereof according to any one of claims 1 to 7, characterised in that the daily dose is 0.05 mg/kg.

9. The use of meloxicam or a pharmacologically acceptable salt thereof according to any one of claims 1 to 8, characterised in that the musculoskeletal disease is osteoarthritis.

10. The use of meloxicam or a pharmacologically acceptable salt thereof according to any one of claims 1 to 9, characterised in that the musculoskeletal disease is a chronic disease.

11. The use of a formulation containing meloxicam or a pharmacologically acceptable salt thereof and one or more vehicles for the manufacture of a medicament for the long-term treatment of musculoskeletal disorders in cats, characterised in that the treatment occurs over a long-term period of from ~~10~~ 13 to 40 months

12. The use of the formulation according to claim 11, characterised in that no negative effects on renal function occur during a treatment from ~~10~~ 13 to 40 months.

13. The use of the formulation according to any one of claims 11 to 12, characterised in that it contains or essentially consists of meloxicam salt, water, optionally one or more additives selected from the group consisting of buffers, solubilizers, preservatives and optionally thickeners.